Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Puma Biotechnology Inc (PBYI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: PBYI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 5.41% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 288.62M USD | Price to earnings Ratio 5.79 | 1Y Target Price 3 |
Price to earnings Ratio 5.79 | 1Y Target Price 3 | ||
Volume (30-day avg) 2 | Beta 1.29 | 52 Weeks Range 2.23 - 5.81 | Updated Date 08/15/2025 |
52 Weeks Range 2.23 - 5.81 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.99 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate 0.09 | Actual 0.15 |
Profitability
Profit Margin 20.35% | Operating Margin (TTM) 12.66% |
Management Effectiveness
Return on Assets (TTM) 14.4% | Return on Equity (TTM) 63.24% |
Valuation
Trailing PE 5.79 | Forward PE 3.46 | Enterprise Value 241830242 | Price to Sales(TTM) 1.21 |
Enterprise Value 241830242 | Price to Sales(TTM) 1.21 | ||
Enterprise Value to Revenue 1.02 | Enterprise Value to EBITDA 3.82 | Shares Outstanding 50370700 | Shares Floating 38753723 |
Shares Outstanding 50370700 | Shares Floating 38753723 | ||
Percent Insiders 15.43 | Percent Institutions 67.88 |
Upturn AI SWOT
Puma Biotechnology Inc
Company Overview
History and Background
Puma Biotechnology, Inc. was founded in 2011. It focuses on the development and commercialization of innovative pharmaceutical products to enhance cancer care.
Core Business Areas
- Development and Commercialization of Oncology Products: Focuses on developing and bringing to market pharmaceutical products for the treatment of cancer.
Leadership and Structure
Alan H. Auerbach is the Chairman, President, and CEO. The company has a standard corporate structure with departments for research, development, commercialization, and finance.
Top Products and Market Share
Key Offerings
- Nerlynx (neratinib): Nerlynx is an oral tyrosine kinase inhibitor approved for extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy. Competition includes other HER2-targeted therapies like Enhertu (Daiichi Sankyo/AstraZeneca) and Kadcyla (Roche). Nerlynx 2023 Revenue was approx $200M. Puma has around ~10% market share of the HER2+ breast cancer market.
Market Dynamics
Industry Overview
The oncology market is characterized by high growth, driven by increasing cancer incidence, aging populations, and advances in targeted therapies and immunotherapies. It's a highly competitive landscape with numerous companies developing and marketing cancer treatments.
Positioning
Puma Biotechnology is a smaller player in the oncology market, focused on HER2-positive breast cancer. Its competitive advantage lies in Nerlynx's specific indication and oral administration.
Total Addressable Market (TAM)
The global breast cancer therapeutics market is estimated to reach over $40 billion. Puma is well positioned to capture market share.
Upturn SWOT Analysis
Strengths
- Approved product (Nerlynx)
- Focus on HER2-positive breast cancer
- Experienced management team
Weaknesses
- Reliance on a single product
- Relatively small market capitalization
- Competition from larger pharmaceutical companies
Opportunities
- Expansion into new indications for Nerlynx
- Partnerships and collaborations
- Geographic expansion
Threats
- Competition from new therapies
- Patent expiration
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- AZN
- RHHBY
- MRK
- PFE
Competitive Landscape
Puma faces intense competition from larger pharmaceutical companies with established oncology portfolios and greater resources.
Growth Trajectory and Initiatives
Historical Growth: Growth has been tied to the uptake of Nerlynx.
Future Projections: Future growth depends on expanding Nerlynx's label and potential collaborations.
Recent Initiatives: Puma is likely focused on lifecycle management for Nerlynx and exploring potential new indications.
Summary
Puma Biotechnology is a small company with a single approved product, Nerlynx, targeting HER2-positive breast cancer. The company faces strong competition from larger pharmaceutical companies. Puma needs to expand indications and find strategic initiatives for sustained growth or it may be targeted for acquisition due to its niche product. Puma needs to focus on reducing costs or increasing revenues.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Press Releases
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market data and analyst estimates are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Puma Biotechnology Inc
Exchange NASDAQ | Headquaters Los Angeles, CA, United States | ||
IPO Launch date 2012-04-24 | Founder, Chairman, President, CEO & Secretary Mr. Alan H. Auerbach | ||
Sector Healthcare | Industry Biotechnology | Full time employees 172 | |
Full time employees 172 | |||
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.